App

China conditionally approves recombinant protein COVID-19 vaccine
Updated: March 2, 2022 19:42 Xinhua

BEIJING — China conditionally approved the registration application of a self-developed recombinant protein subunit vaccine against COVID-19, the National Medical Products Administration said on March 2.

The vaccine, developed by Anhui Zhifei Longcom Biopharmaceutical Co Ltd, was allowed to enter the market on a conditional basis, said the administration.

It marked the first approved COVID-19 recombinant protein subunit vaccine in China.

Copyright© www.gov.cn | About us | Contact us

Website Identification Code bm01000001 Registration Number: 05070218

All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to www.gov.cn.

Without written authorization from www.gov.cn, such content shall not be republished or used in any form.

Mobile

Desktop

Copyright© www.gov.cn | Contact us

Website Identification Code bm01000001

Registration Number: 05070218